Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection in an Immunocompromised Host Clear all

Conditions: COVID-19 Infection
Interventions: ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 69
States / cities: Canoga Park, California • Granada Hills, California • La Jolla, California + 25 more

Conditions: COVID-19
Interventions: Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir, Placebo for ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: San Francisco, California • Washington D.C., District of Columbia • Doral, Florida + 15 more

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Candidiasis, Candidemia
Interventions: voriconazole (Vfend); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more

Conditions: Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
Interventions: Remdesivir, Survey Administration, Biospecimen Collection, Nasal Swab; Drug · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Duarte, California • Houston, Texas • Seattle, Washington

Conditions: Influenza
Interventions: Trivalent Subviron Influenza vaccine (Fluzone); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Roche Global Development; Other
Eligibility: 3 Months to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more

Conditions: Parainfluenza
Interventions: DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose; Drug
Lead sponsor: Ansun Biopharma, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Palo Alto, California + 18 more

Conditions: Influenza
Interventions: Oseltamivir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more

Conditions: Pharmacokinetics
Interventions: Voriconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Chicago, Illinois • New Orleans, Louisiana • Durham, North Carolina + 5 more

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 32
States / cities: Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 28 more

Conditions: Infection, Pulmonary Complications
Interventions: amphotericin B deoxycholate, voriconazole; Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 12 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Wethersfield, Connecticut

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions: Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Cooperstown, New York • New York, New York

Conditions: Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
Interventions: Viral Specific VST Infusion; Biological
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Days and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 4
States / cities: Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio

Search by objective public record fields.

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Influenza Vaccine in Pediatric Transplant Subjects

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

Third Party Viral Specific T-cells (VSTs)